💻 Technology · Next Week

Nobel Prize in Physiology or Medicine 2026 awarded for GLP-1 incretin research (Jens Juul Holst, Svetlana Mojsov and/or Daniel J. Drucker; announcement October 5, 2026)

Miss ✦ AI-generated prediction Published on 26. September 2026 · Predicted for 5. October 2026 · Based on: Speculative

Probability

23%

Jens Juul Holst (University of Copenhagen), Svetlana Mojsov (Rockefeller University) and Daniel J. Drucker (Lunenfeld-Tanenbaum Research Institute, Toronto) were named Clarivate Citation Laureates 2026 on September 17, 2026 for GLP-1 foundational research — the basis for semaglutide (Ozempic/Wegovy) and tirzepatide. Lotte Bjerre Knudsen (Novo Nordisk) is cited as pharmacological complement. GLP-1 is rated the leading candidate field for the 2026 Medicine Nobel by medium.com and oneseventynine.ai. With ~15 competing candidate constellations, single-field probability is approximately 20–25%; no dedicated Polymarket market available.

Data basis for this prediction

Clarivate Citation Laureates 2026: Holst, Mojsov, Drucker für GLP-1 (stdaily.com, 17.09.2026)
medium.com/CassieWelander: GLP-1 als #1-Favorit Medizin-Nobel 2026 (Sep 2026)
oneseventynine.ai: KI-Nobel-Prognosen Medizin 2026 – GLP-1-Feld führend (Stand: Sep 2026)
nobelprize.org: Bekanntgabe Physiologie/Medizin am 5. Oktober 2026, 11:30 CEST

Verdict: Miss

Der Nobelpreis für Physiologie oder Medizin 2026 ging NICHT an die GLP-1-Inkretinforschung. Stattdessen wurde er am 5. Oktober 2026 an Karl Deisseroth (Stanford), Peter Hegemann (Humboldt-Universität Berlin) und Georg Nagel (Universität Würzburg) für die Entdeckung lichtgesteuerter Ionenkanäle und die Entwicklung der Optogenetik verliehen. Holst, Mojsov und Drucker gingen leer aus. Quellen: CNN (https://www.cnn.com/2026/10/05/science/nobel-prize-medicine-karl-deisseroth-peter-hegemann-georg-nagel-intl), Stanford News (https://news.stanford.edu/stories/2026/10/karl-deisseroth-nobel-prize-physiology-medicine), Spektrum.de (https://www.spektrum.de/news/medizin-nobelpreis-2026-fuer-forschung-zur-optogenetik/2345552).

Related Predictions

💻 Technology ✦ AI

Applied Materials Inc. (NASDAQ: AMAT) beats Q4 FY2026 EPS consensus of $4.06 per share — earnings report November 12, 2026 after market close (confirmed by Applied Materials Investor Relations or Bloomberg by November 13, 2026, 10:00 AM ET)

Applied Materials has beaten the EPS consensus in all four of its last reported quarters, with an average earnings surprise of +3.5%. The company's own Q4 guidance is $3.82–$4.22 per share; consensus at $4.06 sits near the midpoint, reflecting classic conservative management framing. Revenue is estimated at $10.30B (+51% YoY) — TSMC and Samsung have not pulled back H2 2026 capex plans. No Polymarket market directly available; a 100% beat streak over 4 quarters with a positive guidance range implies 70–75% probability. Risk: supply chain delays or expanded US export controls on advanced chips could force a Q5 inventory build.

72%

Next Week · Predicted for 12. Nov 2026

💻 Technology ✦ AI

Palantir Technologies Inc. (NYSE: PLTR) closes above $185.00 per share on at least one trading day in November 2026 — confirmed by Nasdaq or Bloomberg by December 1, 2026

PLTR closed at $175.40 on November 4, 2026 (after-hours: $170.88, -2.58%; intraday high: $176.54; 52-week high: $212.94). Palantir clearly beat Q3-FY2026 EPS consensus: total revenue $2.313B, US Commercial revenue +148% YoY to $984M. The $185 threshold is +5.5% above the closing price or +8.3% above after-hours levels. Typical post-earnings 'sell the news' may weigh short-term, but the 52-week high of $212.94 confirms the level is reachable. NVIDIA earnings on November 18, 2026 could serve as a sector-wide catalyst. No direct Polymarket equivalent; own estimate: ~42%.

42%

Next Month · Predicted for 30. Nov 2026

💻 Technology ✦ AI

Cerebras Systems (NASDAQ: CBRS) closes below $100.00 per share on November 10, 2026 (confirmed by Nasdaq or Bloomberg by November 11, 2026)

CBRS trades at $109.18 (October 30, 2026) — already 61% below its all-time high of $279.72. The final and largest lockup expiration is scheduled for November 10, 2026: approximately 19.4 million shares are unlocked (of three tranches of 19.4M each). Prior lockup tranches have consistently weighed on the stock. Insiders have sold ~$394.6M in shares since the May 2026 IPO — zero insider purchases. A Culper Research short-seller report has triggered multiple investigations. A close below $100 requires a ~8.4% decline — plausible given the expected supply pressure on expiration day.

62%

Next Week · Predicted for 10. Nov 2026